BioSpace

After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral

After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.
BioSpace

FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution

Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been ...
BioSpace

ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

In this episode of Denatured, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, ...
BioSpace

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral Wegovy in blood sugar control ...
BioSpace

Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.